Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in infants younger than 1 year. Premature infants, infants with chronic lung disease, infants with major congenital heart diseases, or infants with severe immunodeficiencies are at highest risk of hospital admission for RSV. Palivizumab, a monoclonal antibody, reduces pulmonary viral replication by 100-fold at serum drug levels greater than 40 μg/mL in the cotton rat model. 1 On the basis of randomized clinical trials, monthly administration of 15 mg/kg of palivizumab reduces hospitalizations by approximately 55% in these infants.
2 However, the costliness of this drug restrains its broader use. The American Academy of Pediatrics recommends a maximum of 5 palivizumab doses in selected risk groups during the RSV season, 2 although pharmacokinetic analyses suggest that equivalent antibody protection may be sustainably achieved with fewer doses.
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Methods | In British Columbia, administration of palivizumab necessitates central approval through the British Columbia RSV Immunoprophylaxis Program, and eligible infants are closely followed up by program-coordinated clinics across the province. The RSV season extends from November to April, with the first and last palivizumab doses given the closest day to November 15 and on April 15, respectively. All infants receive a maximum of 3 or 4 doses based on criteria listed in the Abbreviations: BPD, bronchopulmonary dysplasia; CHD, congenital heart disease; CLD, chronic lung disease. a Risk factor score is calculated as follows: Infant attends day care regularly during first 3 months after discharge (22 points); discharged home in December, January, or February (20 points); discharged home in November or March (10 points); gestational age at birth of 29 weeks to less than 31 weeks of completed gestation (10 points); more than 5 people living in household (12 points); sibling younger than 5 years (14 points); remote community, travel of more than 1 hour or of more than 100 km required to the nearest hospital (10 points); girl not receiving breast milk, or boy (8 points); birth weight less than 10th percentile (8 points); and 2 or more smokers in household (8 points).
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Results | We report our population-based intent-to-treat analysis with 100% follow-up rate. Since we adopted this abbreviated program, 514 infants and 666 infants have been approved in the 3-and 4-dose schedules for 4 (2010-2014) and 2 seasons (2012) (2013) (2014) , respectively. In the 3-dose cohort, 1 of 514 infants (0.2%) was hospitalized with RSV during the scheduled dosing period, and 1 was hospitalized 58 days after the third dose. In the 4-dose cohort, 10 infants (1.5%) were hospitalized with RSV during the scheduled dosing period, and 2 twins (0.3%) were hospitalized 65 days after the fourth dose. Moreover, 7 infants (1.4%) and 18 infants (2.7%) in the 3-dose and 4-dose cohorts, respectively, were hospitalized for acute bronchiolitis with no viral studies performed (unspecified cause) within the scheduled dosing period. No infants in either cohort were hospitalized for unspecified bronchiolitis beyond the same period. These outcomes are comparable to historical cohorts treated under the 5-dose regimen.
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Our results agree with end-of-season RSV neutralizing serum antibodies measured in a subgroup of program infants approved to receive 3 or 4 doses of palivizumab. Before the first palivizumab dose, antibody titers in all infants were below protective levels, consistent with low preexisting immunity (Figure) . In contrast, a first palivizumab dose resulted in RSV neutralizing antibody titers above protective equivalents in infants in our abbreviated dose program. In these infants, protective neutralizing antibody levels persisted beyond the end of the RSV season (Figure) .
Discussion | The RSV neutralizing antibodies comprise palivizumab and natural immunity against the virus, which is important because preexisting antibodies correlate best with protection against infection in humans. 6 In summary, our experience in British Columbia provides real-world evidence of adequate protection using an abbreviated palivizumab dosing schedule in infants at higher risk for RSV hospitalization. These data have considerable resource implications for RSV prevention in other medical jurisdictions. 
End of Season Adults Infants Adults
A subset of infants approved to receive either 3 or 4 doses of palivizumab were tested before any palivizumab dose, between 1 and 5 days after a first dose of palivizumab, and at the end of the RSV season (at least 30 days after the last palivizumab dose or after April 15, whichever came last). The RSV neutralizing antibody titers were also determined in season-matched healthy adults. The RSV neutralizing serum antibody titer equivalents (NT95) are based on the ability of a serum dilution (expressed as 1/titer) to inhibit 95% or more of viral infection. In this assay, we determined that palivizumab serum concentrations of 40 μg/mL correspond to a median neutralizing antibody titer of 1:12 (dotted line with minimum and maximum values [shaded area from 3 independent experiments performed in duplicate]). Detection limit was NT95 of approximately 4 (or 1/4), equivalent to a serum concentration of palivizumab of approximately 6.25 μg/mL except for predose serum samples for which the detection limit of the assay was NT95 of approximately 2. Error bars represent median with interquartile range.
Hospitalizations of Low-Income Children and Children With Severe Health Conditions: Implications of the Patient Protection and Affordable Care Act
Medicaid reimbursement often falls below health care costs (Medicaid shortfall). Therefore, hospitals face financial losses from caring for both uninsured and Medicaid-insured patients. The US government provides disproportionate share hospital (DSH) payments to institutions with large uninsured and Medicaid populations. Anticipating decreased numbers of uninsured patients, the Patient Protection and Affordable Care Act (ACA) reduces DSH payments.
1 The ACA also penalizes hospitals for readmissions. 2 There will not be large decreases in the number of uninsured children since only a small percentage of children are uninsured. In contrast, a high percentage of children have Medicaid insurance, and institutions will continue to face Medicaid shortfalls. The loss of DSH payments may not be matched by reductions in financial losses from decreases in the number of uninsured patients. In addition, the readmission penalties of the ACA may not adequately adjust for low-income patients or patients with severe health conditions, thereby adversely affecting hospitals with high proportions of these patients. 3 We sought to determine which hospitals with pediatric patients may be at highest financial risk from decreases in DSH payments and readmission penalties by identifying hospitals with a disproportionate per-hospital number of discharges of pediatric patients receiving Medicaid and those with a disproportionate per-hospital number of discharges of low-income patients or those who have severe health conditions, respectively. For patient mix within hospital types, there were similar distributions of payor type (range, 46%-47% for Medicaid recipients and 2%-4% for the uninsured) and HI (range, 24%-29% for the lowest HI) ( Table 2 ). In contrast, 172 230 (43.0%) children's hospital discharges were children in the highest illness severity category compared with 94 119 (24.5%) discharges of such children from nonteaching hospitals. Similarly, 78 408 (41.0%) children discharged from a freestanding children's hospital had a complex chronic condition compared with 46 520 (12.1%) children discharged from nonteaching hospitals.
Discussion | Analysis of more than 1 million pediatric hospitalizations in 26 states demonstrated that, although nonchildren's teaching hospitals were the most common hospital type for patients with Medicaid, those with the lowest HI, and those with the highest severity of health conditions, the perhospital burden of those discharges was much greater for children's hospitals. Moreover, children's hospitals cared for most of the chronically ill patients and had the greatest proportion of discharges of patients with complex chronic conditions.
Our study has several limitations, including the use of community-level HI as a proxy for patient-level socioeconomic status and the exclusion of "observation status" discharges in the Kids Inpatient Database.
Children's hospitals may face disproportionate financial risk from the ACA. Reductions in DSH payments may disproportionately affect children's hospitals because of their high per-hospital number of Medicaid discharges. In addition, readmission penalties may disproportionately affect children's
